A Phase I Trial of Vemurafenib in Combination With Cetuximab and Irinotecan in Patients With BRAF V600 Mutant Advanced Solid Malignancies
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 30 May 2019
Price : $35 *
At a glance
- Drugs Vemurafenib (Primary) ; Cetuximab; Irinotecan
- Indications Colorectal cancer; Solid tumours
- Focus Adverse reactions
- 24 May 2019 Planned number of patients changed from 35 to 33.
- 24 May 2019 Planned End Date changed from 1 Feb 2019 to 31 Mar 2024.
- 24 May 2019 Planned primary completion date changed from 1 Feb 2019 to 31 Mar 2024.